—
C+
C+ The full Closelook — membership. Open the C+ overview

Summit Therapeutics PLC (SMMT) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Summit Therapeutics PLC

SMMT in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Summit Therapeutics develops cancer treatments, with its lead candidate ivonescimab, a bispecific antibody that blocks PD-1 signalling while also limiting blood-vessel growth around tumours. It is being tested in combination with chemotherapy for lung and colorectal cancers in late-stage trials, and the company sells across several regions worldwide. Summit was founded in 2003 and is headquartered in Miami, Florida.
Where it sits in the stack
Summit carries no Closelook index seat and sits outside our AI build-out framework; it belongs to the Healthcare sector, within Biotechnology, in our wider universe.
Who it is priced against
Closelook has not assigned Summit to a peer group. The market often compares ivonescimab, through its PD-1 mechanism, with Merck's pembrolizumab as an established reference point.
Why Closelook tracks it
Summit holds no index seats in the diary. It carries a Closelook score, but only one module has been scored so far, so the read is still being built.
What the diary watches
Whether the late-stage trial results for ivonescimab, alone or with chemotherapy, confirm the activity seen in earlier studies across the cancer types being tested.

Summit Therapeutics PLC (SMMT) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for SMMT, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: upgrade by Bernstein, 2026-08-25

The Street on this name

Analyst actions and the latest print for SMMT from the Closelook wires — third-party opinions on the record, not our readings.

  • Upgrade Bernstein — Underperform → Market Perform Upgraded to Market Perform from Underperform 2026-08-25

1 action on the analyst wire since 2026-08-13: 1 upgrade. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against SMMT on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Summit Therapeutics PLC (SMMT)?

Summit Therapeutics PLC trades as SMMT on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is SMMT in a Closelook index?

Not currently — Summit Therapeutics PLC is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does SMMT trade against its moving averages?

Recovery attempt under the 200-day: Trades +21.7% vs the 50-day and +8.6% vs the 200-day average, 38.9% below the 52-week high and +47.9% off the 52-week low; a death cross printed 61 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Summit Therapeutics PLC do?

Summit Therapeutics develops cancer treatments, with its lead candidate ivonescimab, a bispecific antibody that blocks PD-1 signalling while also limiting blood-vessel growth around tumours. It is being tested in combination with chemotherapy for lung and colorectal cancers in late-stage trials, and the company sells across several regions worldwide. Summit was founded in 2003 and is headquartered in Miami, Florida. Closelook has not assigned Summit to a peer group. The market often compares ivonescimab, through its PD-1 mechanism, with Merck's pembrolizumab as an established reference point.

Where does Summit Therapeutics PLC sit in the AI build-out?

Summit carries no Closelook index seat and sits outside our AI build-out framework; it belongs to the Healthcare sector, within Biotechnology, in our wider universe. Summit holds no index seats in the diary. It carries a Closelook score, but only one module has been scored so far, so the read is still being built.

What has Wall Street done on Summit Therapeutics PLC recently?

The most recent analyst action on Summit Therapeutics PLC on the Closelook wire is a upgrade by Bernstein on 2026-08-25 (Underperform → Market Perform). 1 action on the analyst wire since 2026-08-13: 1 upgrade. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for SMMT, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.